Antibody-Drug Conjugate Production
Antibody-drug conjugate (ADC) production involves precise engineering of targeted cancer therapies by linking
cytotoxic drugs to specific antibodies. This process includes selecting and producing a monoclonal antibody,
designing a stable linker, and conjugating the drug to the antibody. Key steps also involve purification,
characterization, and validation to ensure the ADC's stability, homogeneity, and efficacy. ADC application
offers advantages like targeted delivery of potent drugs enhancing the therapeutic outcome, reduced side effects
(in particular decreasing off-target toxicity), and the ability to treat challenging or rare cancers by
recognizing and binding to their unique surface antigens.
Chemspace's trusted partner with years of expertise and experience in this field ensures the development of an
efficient procedure for conjugating the antibody of your interest with a potent payload. Chemspace, with access
to a vast chemical space of molecules and advanced chemical synthesis capabilities, can offer the selection of
the most effective linker to connect the antibody and the cytotoxic drug payload.
We offer:
Please get in touch with us for any questions at [email protected].
- Broad range of ADC linkers;
- High purity and homogeneity;
- High stability;
- Fast turnaround time;
- Competitive prices;
- Excellent customer service standards.